A Multi-Omic Platform for Polycystic Ovary Syndrome Characterization and Management

用于多囊卵巢综合征特征和管理的多组学平台

• 批准号: 10080951
• 负责人: Christopher Mason
• 金额: $ 15.55万
• 依托单位: ONEGEVITY HEALTH LLC
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-22 至 2022-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10080951
• 关键词: Age; Animals; Anovulation; Artificial Intelligence; Bacteria; Bacteriophages; Biological Assay; Blood; Cardiovascular system; Clinical; Clinical Trials; Cohort Studies; Complex; Computational algorithm; Computer Models; Consensus; Control Groups; Custom; DNA; Data; Data Reporting; Data Set; Development; Diagnosis; Disease; Endocrine System Diseases; Evaluation; Functional disorder; General Population; Genomics; Goals; Health; Home environment; Hormones; Hyperandrogenism; Individual; Infertility; Irritable Bowel Syndrome; Lead; Literature; Measures; Medical; Metabolic; Metagenomics; Methods; Modality; Molecular; Molecular Profiling; Monitor; Morphology; Multiomic Data; Nature; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Oligonucleotides; Ovarian; Patient Self-Report; Patients; Phenotype; Plants; Polycystic Ovary Syndrome; Pregnancy Complications; Prevalence; Prevention; Probiotics; Recommendation; Risk; Sampling; Self Management; Serum; Shotguns; Spontaneous abortion; Symptoms; System; Technology; Testing; Urine; Variant; Virus; Vitamins; Woman; Work; base; cardiovascular health; convolutional neural network; cost effective; design; diagnostic biomarker; diet and exercise; genome sequencing; gut microbiome; improved; indexing; metabolomics; metagenome; metagenomic sequencing; microbiome; multiple omics; next generation; next generation sequencing; novel; ovarian dysfunction; patient health information; personalized intervention; prebiotics; prospective; reproductive; small molecule; symptom management; whole genome

Project Summary/Abstract Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. Due to the complex nature of PCOS, diagnosis is often delayed and options for treatment and self-management are limited. With recent developments in high-throughput, next- generation and metabolomics technologies, there is now a unique opportunity to utilize a cost- effective, multi-omic approach to study individuals with PCOS. In this application, we propose to apply these technologies to examine women with PCOS, developing a platform that is cost-effective, scalable, integrative, and highly accurate. Our multi- omic platform (FemBio) will integrate patient’s medical records, genomics, microbiome (shotgun metagenomics), and metabolomics to create a molecular profile of women with and without PCOS. This approach has the potential to provide a more comprehensive characterization of PCOS, to lead to the identification of improved diagnostic markers, and to allow for the discovery of novel targets for treatment. Moreover, we propose a prospective observational cohort study including whole genome sequencing, shotgun metagenomic sequencing of the gut microbiome, fecal metabolomics, serum and urine hormone levels, and clinical indices in a sample of individuals with PCOS and a healthy control group. This platform (FemBio) will enable broader accessibility to the latest in molecular assays, multi- omic quantification, and computational modeling for the general public, which currently is lacking. In turn, this will improve options for PCOS characterization, long-term management, and open potentially new treatment options for the millions of women suffering from this disorder, as well as serve as a large, annotated multi-omic data set that can help the PCOS field more broadly.

项目总结/文摘